Drug safety Risks

Sep 24, 2022 | 0 comments

By Martha Rosenberg

Stay Hidden As HYPOCHONDRIA Is Created By Marketing

If you’re like most people, you never heard of the prescription drug Humira until 2013. That’s when Abbott Laboratories spun off AbbVie, to aggressively market the rheumatoid arthritis (RA) drug which went on to become the top selling drug by 2019. Humira marketing is a case study in how drug makers promote expensive, dangerous and, often, unnecessary prescription drugs risking public safety and at taxpayer expense.

Before creating AbbVie, Abbott had already lobbied Congress successfully to get Humira covered by Medicare and seeded seniors with “free samples” to create “demand.” Today Humira costs $2,984 per one syringe, pricing which the U.S. Congress is investigating. The cost of the Medicare-reimbursed Humira has been raised 27 times since the drug’s launch.

AbbVie then created a “nurse ambassador” program according to the Milwaukee Journal Sentinel in which registered nurses were paid to go to the homes of people taking Humira to assure compliance and downplay risks. At least 179,000 patients were reached through the nurse program according to a Journal source and doctors allegedly received kickbacks from the program.

Meanwhile the television airwaves in the United States were saturated. Humira is arguably the most advertised prescription drug on TV and even increased its presence during the COVID-19 pandemic as more lockeddown people watched TV. According to Fierce Pharma, AbbVie spent $52.9 million advertising Humira in April, 2020, double the ad budget of its next closest competitors which were also high.

According to the Journal Sentinel, between 2013 and 2017, AbbVie also greased the palm of the American Academy of Dermatology to the tune of $2 million in grants and donations. Another marketing tactic is indication creep — the successful addition of new indications like uveitis, hidradenitis suppurativa, plaque psoriasis, juvenile idiopathic arthritis and ankylosing spondylitis to Humira once its RA indication was FDA approved.

Humira Drug Safety Risks

Even before the creation of AbbVie, Humira was linked to serious and sometimes lethal side effects. In 2008, the Associated Press reported 240 people had contracted the fungal infection histoplasmosis from Humira and similar drugs — and that 20 percent died.

Current Humira prescribing information reads, “Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including HUMIRA. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including HUMIRA. These cases have had a very aggressive disease course and have been fatal.”

More Drug Safety Risks and Hypochondria

Many have observed that raising “awareness” of a disease — whether RA or ankylosing spondylitis — increases self-diagnosis and drug sales, even hypochondria. The proof is that “unbranded” disease awareness advertising (that mentions neither the medication being sold or the sponsor) constitutes a big part of drug maker budgets. The “sale” occurs when the disease is searched online revealing symptom quizzes and even “scripts” to recite during the suggested doctor visit. (Yes, patients are doing drug reps’ work for free.)

For example, AbbVie “Face Your Back Pain” campaign has tried to sell its ankylosing spondylitis drugs through convincing people they have “AS.”*

Currently, AbbVie is selling “EPI,” short for exocrine pancreatic insufficiency. Despite the COVID-19 pandemic, wildfires, hurricanes, mass shootings, lead in water systems, oil spills, earthquakes and floods, the ads would have us believe the real risk people face today is EPI — a disease so obscure that few of the doctors with whom I work have ever encountered it.

“My number two does not look like a number two. I don’t know what to call it,” began an old AbbVie radio ad for EPI with the payoff line, “Don’t Keep a Lid on It.” Currently, AbbVie’s radio ads sport a man and woman suggestively asking in unison “Could I have EPI?” and telling listeners to get more specific with their doctors. Creon, the drug AbbVie is selling for EPI, contains animal derived pancreatic enzymes and sells for several hundred dollars. Like Humira, the risks listed on its prescribing information are alarming.

Money Over Safety

In the countries where direct-toconsumer drug advertising exists, many say it has not improved public health but promoted unsafe drugs and hypochondria. Moreover, since drug makers are major funders of news media, the huge ad revenues may explain why unsafe drugs and unethical marketing is very underreported.

Best Case Leads Celebrates Sixth Consecutive Year on Inc. 5000 List of Fastest-Growing Private Companies in America

Aug 19, 2025 | Press Releases Houston, TX, August 18, 2025 — Best Case Leads, a pioneering leader in legal lead generation, proudly announces its sixth consecutive recognition on the prestigious Inc. 5000 fastest-growing private companies in...

Baby Formula Litigation, NEC Claims, and the Evolving Landscape of Mass Torts

By Fadi Agour, J.D. Families of premature infants who developed necrotizing enterocolitis (NEC) after being fed cow–milk–based formula products like Similac and Enfamil continue to pursue justice in both state and federal courts. Recent...

Mass Tort Landscape 2025: Key Cases, Trends & Strategic Opportunities

The mass tort landscape is evolving rapidly, with new cases gaining momentum and established litigations reaching critical phases. For law firms and legal marketers, timing is everything—success hinges on anticipating trends, securing high-value claimants early, and...

Zyprexa & Risperdal 2: The Breast Cancer Link That Could Ignite the Next Mass Tort

The pharmaceutical litigation landscape has seen its share of blockbuster cases—from opioid multidistrict litigations to the ongoing Paraquat Parkinson’s claims. But a new California lawsuit (Brown v. Johnson & Johnson et al.) could revive two legacy antipsychotics...

Mass Torts in 2025: A Legal Landscape in Flux

As 2025 unfolds, the world of mass tort litigation shows no signs of slowing down. From pharmaceutical giants to tech behemoths, corporations across industries are facing an unprecedented wave of lawsuits that could reshape their futures. With judges issuing critical...

The PFAS Contamination Crisis: A Deep Dive into the Mass Tort Litigation and Its Implications

Per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a focal point of environmental and public health concerns in the United States. These synthetic chemicals, used for their water, heat, and grease-resistant properties,...

The Ultra-Processed Foods Lawsuit: A Must-Know Update for Mass Tort Lawyers

Ultra-processed foods (UPFs) have become a cornerstone of modern diets, but their convenience comes at a cost. As consumption of these foods has skyrocketed, so too have the alarming health complications linked to them, including obesity, diabetes, heart disease, and...

Understanding the BioZorb Litigation: A Growing Legal Battle for Plaintiff Attorneys

What is BioZorb? The BioZorb litigation is shaping up to be one of the most significant legal challenges of 2025, presenting a unique opportunity for plaintiff attorneys nationwide. This case revolves around a medical device designed to aid breast cancer patients but...

The Role of Technology in Optimizing Workers’ Compensation Lead Generation

The process of generating and managing workers' compensation leads has undergone a significant transformation with the advent of technology. Modern tools and software solutions are now indispensable in streamlining operations, improving lead quality, and enhancing...

How to Build a Referral Network for Mass Tort Cases

Mass tort cases often involve a large number of claimants seeking justice for harm caused by a common defendant, such as pharmaceutical companies or manufacturers. For attorneys specializing in these cases, building a robust referral network can significantly boost...

Ready to Start Receiving Qualified Leads?

Get exclusive, real-time legal leads delivered to your firm.

Get Started